Seeking Alpha

Seeking Alpha Portfolio App for iPad

Smith On Stocks

Smith On Stocks picture

Smith On Stocks

Profile

1,338 Followers

Send Message

View as an RSS Feed

View Smith On Stocks' Articles BY TICKER:

Teva Partnership And Pipeline Potential: Why Antares Is A Buy
on Thu, Jan 26, 2012 • PFE, TEVA, ATRS • 14 Comments
Update On The Trials Of Catalyst Pharma's CPP-109 In Cocaine Addiction And CPP-115 Pre-Clinical Studies
on Wed, Jan 25, 2012 • CPRX • 1 Comment
Cadence's Ofirmev Launch Is Gaining Traction
on Wed, Jan 25, 2012 • CADX • 6 Comments
Transcept's Intermezzo Has Significant Long-Term Potential, But What About 2012?
on Tue, Jan 24, 2012 • AUXL, CADX, TSPT • 11 Comments
Catalyst Pharma: Awaiting Key Clinical Trial Results For CPP-109 For Treating Cocaine Addiction
on Tue, Jan 24, 2012 • CPRX • 4 Comments
Pharmasset, Inhibitex Receive Takeover Bids - Is Achillion Next?
on Mon, Jan 9, 2012 • VRUS, INHX, ACHN • 5 Comments
Dendreon: Provenge Sales Surprise On Upside, Bodes Well For The Stock
on Fri, Jan 6, 2012 • JNJ, MDVN, DNDN • 10 Comments
MAP's Levadex: Blockbuster Potential With A March 26 PDUFA Date
on Wed, Dec 14, 2011 • AGN, MAPP • 1 Comment
Antares: Phase III Trial Results For Libi-Gel Are Imminent
on Wed, Dec 14, 2011 • BPAX, PG, WCRX • 7 Comments
An Overview Of Antares' And Teva's Collaboration On Self-Injection Drugs
on Tue, Dec 13, 2011 • TEVA, ATRS • 1 Comment
Approval Of Anturol Is A Major Positive For Antares
on Fri, Dec 9, 2011 • ACT, PFE, ATRS • 26 Comments
Savient's Krystexxa: How I Get A $209 Million Sales Estimate By 2015
on Wed, Dec 7, 2011 • BCRX, RDEA, SVNT • 9 Comments
Antares Pharma's Anturol Approaches PDUFA Date
on Tue, Dec 6, 2011 • ACT, ATRS • 17 Comments
Savient Pharmaceuticals: Thoughts On The Chronic Refractory Gout Market
on Tue, Dec 6, 2011 • SVNT • 9 Comments
Antares Pharmaceuticals: A Buy Based On Exceptional New Product Outlook
on Tue, Dec 6, 2011 • TEVA, PFE, GSK • 19 Comments
Savient Pharmaceuticals: The Potential Role Of Krystexxa In The Treatment Of Gout
on Fri, Dec 2, 2011 • RDEA, BCRX, SVNT • 15 Comments
Savient Pharmaceuticals: Sluggish Launch Of Krystexxa Presents Buying Opportunity
on Wed, Nov 30, 2011 • RDEA, BCRX, SVNT • 13 Comments
Dendreon: Market Ignoring Encouraging Signs
on Tue, Nov 22, 2011 • JNJ, MDVN, DNDN • 12 Comments
Gilead Acquiring Pharmasset - Could Achillion And Inhibitex Be Next?
on Mon, Nov 21, 2011 • GILD, VRTX, MRK • 6 Comments
Adolor's Takeover Bid From Cubist An Attractive Deal For Investors
on Mon, Oct 24, 2011 • CBST, ADLR • 7 Comments
Dendreon Revisited: What Management Is Saying About Provenge
on Mon, Oct 3, 2011 • JNJ, DNDN • 18 Comments
Santarus Plans NDA Filing On Key New Drug
on Mon, Oct 3, 2011 • SNTS • Comment!
Orexigen; FDA Reverses Position And Gives New Life To Contrave
on Wed, Sep 21, 2011 • OREX • 3 Comments
Santarus: Weighing A Promising Pipeline Against Patent Challenges
on Fri, Sep 16, 2011 • DEPO, AZN, ABT • 2 Comments
Transcept Up Sharply On Plan To Resubmit Intermezzo NDA
on Thu, Sep 15, 2011 • TSPT • 1 Comment
Focus On Entereg; Reiterating Buy On Adolor
on Thu, Sep 15, 2011 • ADLR, NKTR, AZN • 2 Comments
Santarus' Late Stage Pipeline Product Budesonide MMX Is Critical To Future Growth
on Wed, Sep 14, 2011 • SNTS, WCRX, SHPG • 3 Comments
FDA Advisory Committee Goes Against FDA, Recommends Approval of JNJ's Xarelto
on Fri, Sep 9, 2011 • JNJ • Comment!
Key Companies And Products In The Market To Treat The Orphan Disease Hereditary Angioedema
on Thu, Sep 8, 2011 • SNTS, VPHM, DYAX • 2 Comments
Johnson & Johnson, Bristol-Myers: Investment Implications Of Rivararoxban's FDA Problems
on Thu, Sep 8, 2011 • BMY, JNJ, PFE • 6 Comments
ImmunoCellular Therapeutics: A Small But Interesting Player In Dendritic Cancer Vaccines
on Wed, Aug 24, 2011 • IMUC • 12 Comments
Dendreon: Assessing Provenge's Effectiveness In Light Of Roche's Zelboraf Approval
on Mon, Aug 22, 2011 • BMY, RHHBY.OB, DNDN • 5 Comments